Tao Wang, PhD | Chinese Academy of Medical Sciences; Xuegang Wang, PhD, MD; Bing Guan, PhD, MD
Competition Sponsor: Chinese Academy of Medical Sciences
Awardee Year: 2025
Prostate cancer (PCa) is the second most commonly diagnosed malignancy among men worldwide and the incidence and mortality rates of prostate cancer in China have been rising annually. There is an urgent need for integrated technological breakthroughs to establish a precise screening system covering the entire disease course of prostate cancer, aiming to achieve early detection, simplify diagnostic procedures for advanced cases, and enable identification of the neuroendocrine transformation (NEPC) subtype. Based on our previous work, we will integrate SERS-based rapid PSA testing, SPR-based detection of PSA, CD63-sEV, and PSMA-sEV, as well as the development of an SV2A-targeted probe for NEPC. Through prospective multi-center cohort studies, we will validate the clinical efficacy of these three technologies. Ultimately, we aim to establish a pioneering three-tier screening model of “SERS Rapid Test-Exosome Sensing-SV2A Imaging”. This model will overcome three major clinical bottlenecks: insufficient sensitivity in early detection, reliance on invasive methods in advanced stages, and the lack of diagnostic tools for NEPC. By doing so, it will promote early screening, diagnosis, and treatment of prostate cancer, advance precision medicine, extend patient survival, improve quality of life, and contribute to the national strategy for health and longevity.